KMCRIC

A randomized, controlled study of treatment with ojayeonjonghwan for patients with late onset hypogonadism.

Lee KW, Bae SR, Jeong HC, Choi JB, Choi SW, Bae WJ, Kim SJ, Cho HJ, Ha US, Hong SH, Kim SW.

Aging Male.

2020

23(4)

264-71.

10.1080/13685538.2018.1480599.

30039982

http://www.ncbi.nlm.nih.gov/pubmed/30039982

Andropause; antioxidants; geriatrics; herbal medicine; sexual dysfunction

남성 갱년기; 항산화제; 노인병 치료; 한약 치료; 성기능 장애

KMCRIC 비평 보기 +

Y

Objectives: We investigate the effects of Ojayeonjonghwan (KH-204) in men with late-onset hypogonadism (LOH) symptoms.

Material and methods: Initial PSA, testosterone, lipid profile and questionnaires about LOH-related symptoms were checked. After 8 weeks of the treatment (control or KH-204), questionnaires and serological tests were repeated to evaluate the efficacy of the agent. The changes of variables in each group and the difference between two groups were compared.

Results: A total of 78 men were enrolled, and randomly assigned to the control group (n = 39) or KH-204 group (n = 39). Baseline characteristics of both group are comparable. AMS total score of control and KH-204 group were both improved at 8 weeks (p = .010, <.001), and there was a statistically significant difference between the two groups (favorable in KH-204 group, p = .006). At 8 weeks, total IIEF score of control and KH-204 group were both improved, and there was no statistically significant difference in the degree of improvement between the two groups (p = .303). There was no statistically significant difference of laboratory findings, in intra-group changes and inter-group comparisons.

Conclusions: KH-204 was found to be effective in all LOH symptoms without changing of laboratory results. KH-204 may be safely used for treatment of male with LOH-related symptoms.

영어